Courtney Dinardo, MD from MD Anderson Cancer Center discusses the results of the phase 3 VIALE-A study, examining the combination of venetoclax and azacitidine as treatment for acute myeloid leukemia (AML). The results of this study showed this combination was more efficacious than azacitidine alone, with patients who received both treatments showing more than double the rate of composite complete remission (66.4%) than those who only received azacitidine (28.3%). The outcome measures were all show to be beneficial for the combination therapy.
The results were presented at the European Hematology Association Virtual Meeting.
AML is an aggressive cancer of the blood and bone marrow with a 5-year survival rate of only 28%. This cancer is particularly lethal for older AML patients who may not be able to tolerate intensive chemotherapy, hence the need for research on the efficacy of combined targeted therapies- such as the combination examined in the VIALE-A study.
For more information about AML and other rare cancers, visit https://checkrare.com/diseases/cancers/